Legend Biotech Valuation
| LEGN Stock | USD 17.58 0.48 2.66% |
At this time, the firm appears to be fairly valued. Legend Biotech Corp secures a last-minute Real Value of $17.06 per share. The latest price of the firm is $17.58. Our model forecasts the value of Legend Biotech Corp from analyzing the firm fundamentals such as Return On Equity of -0.23, current valuation of 2.66 B, and Profit Margin of (0.26) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Legend Biotech's valuation include:
Price Book 3.2107 | Enterprise Value | Enterprise Value Ebitda (15.34) | Price Sales 3.5717 | Forward PE 47.619 |
Fairly Valued
Today
Please note that Legend Biotech's price fluctuation is not too volatile at this time. Calculation of the real value of Legend Biotech Corp is based on 3 months time horizon. Increasing Legend Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Legend Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Legend Stock. However, Legend Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.58 | Real 17.06 | Target 60.6 | Hype 17.58 |
The intrinsic value of Legend Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Legend Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Legend Biotech Corp helps investors to forecast how Legend stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Legend Biotech more accurately as focusing exclusively on Legend Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Legend Biotech's intrinsic value based on its ongoing forecasts of Legend Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Legend Biotech's closest peers.
Legend Biotech Cash |
|
Legend Biotech Total Value Analysis
Legend Biotech Corp is now forecasted to have valuation of 2.66 B with market capitalization of 3.25 B, debt of 350.6 M, and cash on hands of 791.26 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Legend Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.66 B | 3.25 B | 350.6 M | 791.26 M |
Legend Biotech Investor Information
About 50.0% of the company shares are owned by institutional investors. The book value of Legend Biotech was now reported as 5.48. The company recorded a loss per share of 1.28. Legend Biotech Corp had not issued any dividends in recent years. Legend Biotech Corp is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Legend Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Legend Biotech has an asset utilization ratio of 37.56 percent. This suggests that the Company is making $0.38 for each dollar of assets. An increasing asset utilization means that Legend Biotech Corp is more efficient with each dollar of assets it utilizes for everyday operations.Legend Biotech Profitability Analysis
Considering the key profitability indicators obtained from Legend Biotech's historical financial statements, Legend Biotech Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Legend Biotech's ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-03-31 | Previous Quarter -125.4 M | Current Value -39.7 M | Quarterly Volatility 54.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.72 |
|
|
For Legend Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Legend Biotech Corp to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Legend Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Legend Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Legend Biotech over time as well as its relative position and ranking within its peers.
Legend Biotech Earnings per Share Projection vs Actual
By analyzing Legend Biotech's earnings estimates, investors can diagnose different trends across Legend Biotech's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Legend Biotech Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Legend Biotech Ownership Allocation
Legend Biotech Corp maintains a total of 184.69 Million outstanding shares. 30% of Legend Biotech outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Legend Biotech Profitability Analysis
The company reported the previous year's revenue of 627.24 M. Net Loss for the year was (158.13 M) with profit before overhead, payroll, taxes, and interest of 132.68 M.About Legend Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Legend Biotech Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Legend Biotech Corp based exclusively on its fundamental and basic technical indicators. By analyzing Legend Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Legend Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Legend Biotech. We calculate exposure to Legend Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Legend Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 451.6 M | 474.1 M | |
| Pretax Profit Margin | (0.29) | (0.30) | |
| Operating Profit Margin | (0.56) | (0.58) | |
| Net Loss | (0.32) | (0.34) | |
| Gross Profit Margin | 0.72 | 0.70 |
Legend Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 91.4 M | |
| Forward Price Earnings | 47.619 |
Legend Biotech Current Valuation Indicators
Legend Biotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Legend Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Legend Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Legend Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Legend Biotech's worth.When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.7 | Return On Assets | Return On Equity |
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.